Archvest Wealth Advisors Inc. Invests $210,000 in Johnson & Johnson (NYSE:JNJ)

Archvest Wealth Advisors Inc. acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) in the fourth quarter, Holdings Channel reports. The fund acquired 1,455 shares of the company’s stock, valued at approximately $210,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Powers Advisory Group LLC raised its holdings in Johnson & Johnson by 0.6% in the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the company’s stock worth $1,538,000 after purchasing an additional 61 shares in the last quarter. Knuff & Co LLC increased its holdings in shares of Johnson & Johnson by 0.7% during the third quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock valued at $1,534,000 after acquiring an additional 64 shares in the last quarter. Vertex Planning Partners LLC increased its holdings in shares of Johnson & Johnson by 1.3% during the third quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock valued at $844,000 after acquiring an additional 65 shares in the last quarter. Freedom Day Solutions LLC increased its holdings in shares of Johnson & Johnson by 1.1% during the third quarter. Freedom Day Solutions LLC now owns 6,269 shares of the company’s stock valued at $1,016,000 after acquiring an additional 66 shares in the last quarter. Finally, Traphagen Investment Advisors LLC increased its holdings in shares of Johnson & Johnson by 0.6% during the third quarter. Traphagen Investment Advisors LLC now owns 10,483 shares of the company’s stock valued at $1,699,000 after acquiring an additional 67 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 1.3 %

Shares of NYSE:JNJ opened at $156.18 on Wednesday. The stock has a market capitalization of $376.02 billion, a price-to-earnings ratio of 23.49, a PEG ratio of 2.46 and a beta of 0.52. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The stock’s 50-day simple moving average is $147.40 and its two-hundred day simple moving average is $156.04. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same period last year, the firm posted $2.29 earnings per share. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. Johnson & Johnson’s payout ratio is currently 74.59%.

Insider Activity

In related news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of several analyst reports. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Guggenheim raised their price target on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a report on Monday, February 3rd. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. Finally, Wolfe Research started coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective for the company. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.